Literature DB >> 12065492

Clearance of Helicobacter pylori Infection and Resolution of Postimmunization Gastritis in a Kinetic Study of Prophylactically Immunized Mice.

Christine A Garhart1, Raymond W Redline, John G Nedrud, Steven J Czinn.   

Abstract

Patients infected with Helicobacter pylori mount an immune response which fails to clear the infection and may contribute to disease. Mice can be protected by immunization. To further characterize the H. pylori-mouse model, stomachs of unimmunized or intranasally immunized C57BL/6 mice were quantitatively cultured 3 days and 1, 2, 4, 8, 16, 32, and 52 weeks after challenge with H. pylori. At 3 days and 1 week after challenge, colonization was the same in the immunized and unimmunized mice. By 2 weeks after challenge, the immunized mice had a >2-log decrease in bacterial load, and at all later time points, they either were culture negative or had at least a 2-log decrease in bacterial load. Gastritis in the immunized mice peaked at 1 to 2 weeks after challenge and was characterized by a mixed inflammatory infiltrate and epithelial proliferation centered at the transition between corpus and antrum. By 52 weeks postchallenge, the gastric histology in the immunized mice was not different from that in control unchallenged mice. The unimmunized group began to show a reduction in bacterial load as early as 16 weeks after challenge, and by 52 weeks seven of eight unimmunized mice had developed gastritis and reduced bacterial loads. These results indicate that prophylactic immunization does not prevent colonization by H. pylori but enables mice to clear the infection or significantly reduce the number of colonizing bacteria. The reduction in bacterial load is associated with gastric inflammation that subsides over time.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12065492      PMCID: PMC128038          DOI: 10.1128/IAI.70.7.3529-3538.2002

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  45 in total

1.  Gastritis in urease-immunized mice after Helicobacter felis challenge may be due to residual bacteria.

Authors:  T H Ermak; R Ding; B Ekstein; J Hill; G A Myers; C K Lee; J Pappo; H K Kleanthous; T P Monath
Journal:  Gastroenterology       Date:  1997-10       Impact factor: 22.682

2.  Safety of oral immunisation with recombinant urease in patients with Helicobacter pylori infection.

Authors:  C Kreiss; T Buclin; M Cosma; I Corthésy-Theulaz; P Michetti
Journal:  Lancet       Date:  1996-06-08       Impact factor: 79.321

3.  A standardized mouse model of Helicobacter pylori infection: introducing the Sydney strain.

Authors:  A Lee; J O'Rourke; M C De Ungria; B Robertson; G Daskalopoulos; M F Dixon
Journal:  Gastroenterology       Date:  1997-04       Impact factor: 22.682

4.  Detoxification of the Helicobacter pylori cytotoxin.

Authors:  R Manetti; P Massari; M Marchetti; C Magagnoli; S Nuti; P Lupetti; P Ghiara; R Rappuoli; J L Telford
Journal:  Infect Immun       Date:  1997-11       Impact factor: 3.441

5.  Catalase, a novel antigen for Helicobacter pylori vaccination.

Authors:  F J Radcliff; S L Hazell; T Kolesnikow; C Doidge; A Lee
Journal:  Infect Immun       Date:  1997-11       Impact factor: 3.441

6.  T helper 1 effector cells specific for Helicobacter pylori in the gastric antrum of patients with peptic ulcer disease.

Authors:  M M D'Elios; M Manghetti; M De Carli; F Costa; C T Baldari; D Burroni; J L Telford; S Romagnani; G Del Prete
Journal:  J Immunol       Date:  1997-01-15       Impact factor: 5.422

7.  Atrophic gastric changes in both Helicobacter felis and Helicobacter pylori infected mice are host dependent and separate from antral gastritis.

Authors:  T Sakagami; M Dixon; J O'Rourke; R Howlett; F Alderuccio; J Vella; T Shimoyama; A Lee
Journal:  Gut       Date:  1996-11       Impact factor: 23.059

8.  Therapeutic intragastric vaccination against Helicobacter pylori in mice eradicates an otherwise chronic infection and confers protection against reinfection.

Authors:  P Ghiara; M Rossi; M Marchetti; A Di Tommaso; C Vindigni; F Ciampolini; A Covacci; J L Telford; M T De Magistris; M Pizza; R Rappuoli; G Del Giudice
Journal:  Infect Immun       Date:  1997-12       Impact factor: 3.441

9.  Oral immunization with recombinant Helicobacter pylori urease induces secretory IgA antibodies and protects mice from challenge with Helicobacter felis.

Authors:  C K Lee; R Weltzin; W D Thomas; H Kleanthous; T H Ermak; G Soman; J E Hill; S K Ackerman; T P Monath
Journal:  J Infect Dis       Date:  1995-07       Impact factor: 5.226

10.  Novel intranasal immunization techniques for antibody induction and protection of mice against gastric Helicobacter felis infection.

Authors:  R Weltzin; H Kleanthous; F Guirakhoo; T P Monath; C K Lee
Journal:  Vaccine       Date:  1997-03       Impact factor: 3.641

View more
  46 in total

1.  Proinflammatory cytokine gene expression in the stomach correlates with vaccine-induced protection against Helicobacter pylori infection in mice: an important role for interleukin-17 during the effector phase.

Authors:  Carl-Fredrik Flach; Anna Karin Östberg; Anne-Therese Nilsson; Rene De Waal Malefyt; Sukanya Raghavan
Journal:  Infect Immun       Date:  2010-11-15       Impact factor: 3.441

2.  Oral vaccination against Helicobacter pylori infection is not effective in mice with Fas ligand deficiency.

Authors:  Yaron Avitzur; Esther Galindo-Mata; Nicola L Jones
Journal:  Dig Dis Sci       Date:  2005-12       Impact factor: 3.199

3.  Inhibition of H. pylori colonization and prevention of gastritis in murine model.

Authors:  Mahdieh Ameri Shah Reza; Seyed Latif Mousavi Gargari; Iraj Rasooli; Mohammadreza Jalali Nadoushan; Walead Ebrahimizadeh
Journal:  World J Microbiol Biotechnol       Date:  2012-04-28       Impact factor: 3.312

4.  HelicoVax: epitope-based therapeutic Helicobacter pylori vaccination in a mouse model.

Authors:  Steven F Moss; Leonard Moise; Dong Soo Lee; Woojin Kim; Songhua Zhang; Jinhee Lee; Arlin B Rogers; William Martin; Anne S De Groot
Journal:  Vaccine       Date:  2011-01-12       Impact factor: 3.641

5.  Lactobacillus johnsonii La1 attenuates Helicobacter pylori-associated gastritis and reduces levels of proinflammatory chemokines in C57BL/6 mice.

Authors:  Dionyssios N Sgouras; Effrosini G Panayotopoulou; Beatriz Martinez-Gonzalez; Kalliopi Petraki; Spyros Michopoulos; Andreas Mentis
Journal:  Clin Diagn Lab Immunol       Date:  2005-12

6.  Probiotics reduce bacterial colonization and gastric inflammation in H. pylori-infected mice.

Authors:  Kathene Candace Johnson-Henry; David J Mitchell; Yaron Avitzur; Esther Galindo-Mata; Nicola L Jones; Philip M Sherman
Journal:  Dig Dis Sci       Date:  2004-08       Impact factor: 3.199

7.  Chronic Helicobacter pylori infection with Sydney strain 1 and a newly identified mouse-adapted strain (Sydney strain 2000) in C57BL/6 and BALB/c mice.

Authors:  Lucinda J Thompson; Stephen J Danon; John E Wilson; Jani L O'Rourke; Nina R Salama; Stanley Falkow; Hazel Mitchell; Adrian Lee
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

8.  Effect of bacterial flora on postimmunization gastritis following oral vaccination of mice with Helicobacter pylori heat shock protein 60.

Authors:  Hiroyuki Yamaguchi; Takako Osaki; Haruhiko Taguchi; Noriko Sato; Atushi Toyoda; Motomichi Takahashi; Masanori Kai; Noboru Nakata; Akio Komatsu; Yutaka Atomi; Shigeru Kamiya
Journal:  Clin Diagn Lab Immunol       Date:  2003-09

9.  DC-LAMP+ dendritic cells are recruited to gastric lymphoid follicles in Helicobacter pylori-infected individuals.

Authors:  Malin Hansson; Malin Sundquist; Susanne Hering; B Samuel Lundin; Michael Hermansson; Marianne Quiding-Järbrink
Journal:  Infect Immun       Date:  2013-07-22       Impact factor: 3.441

10.  Orally administered CpG oligodeoxynucleotide induces production of CXC and CC chemokines in the gastric mucosa and suppresses bacterial colonization in a mouse model of Helicobacter pylori infection.

Authors:  S Raghavan; J Nyström; M Fredriksson; J Holmgren; A M Harandi
Journal:  Infect Immun       Date:  2003-12       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.